Orforglipron + Phentermine for Obesity

DJ
SK
Overseen BySarah Kanbour, MD
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Massachusetts General Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will compare the effect of orforglipron and phentermine on weight maintenance.

Are You a Good Fit for This Trial?

This trial is for adults who have recently stopped GLP-1 weight loss injections and want to prevent regaining weight. Participants should be generally healthy, interested in managing their weight, and able to take oral medications.

Inclusion Criteria

Willing to participate in the study after reviewing study infographic and confirming understanding of randomization and study procedures
Residence in Massachusetts
History of BMI ≥30 kg/m²
See 4 more

Exclusion Criteria

History of significant active or unstable major depressive disorder or other severe psychiatric disorder within the past 2 years
Any history of a suicide attempt
I have not had or planned obesity surgery within the past year.
See 16 more

What Are the Treatments Tested in This Trial?

Interventions

  • Orforglipron
  • Phentermine

Trial Overview

The study compares two pills—Orforglipron (a new type of weight management drug) and Phentermine (an established appetite suppressant)—to see which helps people keep off the weight after stopping GLP-1 therapy.

How Is the Trial Designed?

2

Treatment groups

Active Control

Group I: PhentermineActive Control1 Intervention
Group II: OrforglipronActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+